相关产品：港股创新药ETF（159567） 2）CRO：①2024年以来，海外CPI月度数据虽有波动，但海外有望逐步进入降息节奏，投融资改善预 期有望边际向好，且部分公司订单已然看到恢复，我们预计海外收入为主的一体化CRO/CDMO及国内 临床前CRO有望迎来估值修复机会；②源于CRO板块受国内外投融资环境、不利因素影响较大，但随 着国内政策逐步发力，我们预计板块有望逐步恢复，持续关注临床CRO投资机会。 截至2025年5月21日 09:47，国证港股通创新药指数(987018)强势上涨2.33%，成分股康希诺生物(06185) 上涨8.87%，君实生物(01877)上涨8.16%，凯莱英(06821)上涨7.02%，亚盛医药-B(06855)，晶泰控股 (02228)等个股跟涨。港股创新药ETF(159567)上涨1.56%， 冲击4连涨。最新价报1.3元。拉长时间看， 截至2025年5月20日，港股创新药ETF近1周累计上涨8.63%。流动性方面，港股创新药ETF盘中换手 10.03%，成交1.71亿元，市场交投活跃。拉长时间看，截至5月20日，港股创新药ETF近1月日均成交 7.36亿元。规模方面，港股 ...

兴业证券认为，创新药景气度可持续，"创新+国际化"创新药产业趋势不变，始终是医药板块的核心方 向，政策支持+全球竞争力持续加强+商业化盈利兑现。同时，可关注基本面开始改善的创新药产业 链，海外业务方面订单和业绩已开始恢复，国内业务具备自主可控逻辑。国内方面，2025年需求有望迎 来复苏，若经济基本面预期转好，消费医疗领域（医疗服务、中药OTC与连锁药店等）基本面有望实现 回升。同时，医疗器械2025年亦有望迎来改善。此外，AI医疗作为科技方向，有望为医药产业带来新 的变化，其产业趋势值得重视。 国元证券指出，5月份开始，将进入业绩真空期，市场关注点由业绩转变为行业和公司基本面变化，我 们继续看好创新药、出海以及集采出清板块。目前我国创新药进入成果兑现阶段，研发进展催化较多， 且不受贸易战影响，有望持续作为2025年医药板块投资主线。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 5月21日早盘，港股市场集体拉升。截至发稿，恒生指数涨0.74%，恒生科技指数涨0.8%。 相关ETF方面，截至发稿，港股创新药ETF（159567）涨1.71%，换手率6.72% ...

港股医药股延续强势，康希诺生物(06185.HK)涨超10%，君实生物(01877.HK)涨超9%，三叶草生物 (02197.HK)、康方生物(09926.HK)等跟涨。 ...

智通财经5月21日电，舒泰神20CM涨停，此前三生国健3连板，赛升药业、海创药业、海辰药业、诺思 格、君实生物等跟涨。消息面上，港股创新药企三生制药公告称，其与辉瑞公司就前者自主研发的PD- 1/VEGF双特异性抗体SSGJ-707签订了独家许可协议。本次协议中12.5亿美元的首付款再次刷新了国产 创新药出海首付款金额纪录。 创新药概念延续强势 舒泰神20CM涨停 ...

上海君实生物医药科技股份有限公司的主营业务是新药的研发及相关技术的转让和服务，新药的生产和 销售。公司的主要产品是特瑞普利单抗、氢溴酸氘瑞米德韦片、Tifcemalimab、阿达木单抗、昂戈瑞西 单抗、重组人源化抗IL-17A单克隆抗体、重组人源化抗PD-1、VEGF双特异性抗体、靶向 ANGPTL3mRNA的siRNA药物、重组人源化抗CGRP单克隆抗体、PI3K-α抑制剂、重组人源化抗 Claudin18.2单抗-MMAE偶联剂。公司拥有175项已授权专利，其中129项为境内专利，46项为境外专 利。公司专利覆盖新药蛋白结构、制备工艺、用途、制剂配方等，为公司产品提供充分的和长生命周期 的专利保护。 5月20日，君实生物今日收盘29.58元，上涨3.57%，最新市净率5.19，创11天以来新低，总市值291.57亿 元。 股东方面，截至2025年3月31日，君实生物股东户数29420户，较上次增加69户，户均持股市值35.28万 元，户均持股数量2.76万股。 本文源自：金融界 最新一期业绩显示，2025年一季报，公司实现营业收入5.01亿元，同比31.46%；净利润-234876226.63 元，同比1 ...

Core Viewpoint - The company received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response about its operational performance and product sales [1][2]. Group 1: Operational Performance - In 2024, the company achieved operating revenue of 200 million yuan, a year-on-year increase of 243.53% [2][19]. - The company has three commercialized products: Junmaikang, Mailishu, and Maiweijian, with varying sales performance and challenges [2][3]. - Junmaikang's sales volume significantly decreased by 66.61%, with 48,821 units shipped in 2024 [2][10]. - Mailishu's sales revenue increased by 195.50%, with a total revenue of 12.44 million yuan in 2024 [3][5]. - Maiweijian achieved a total revenue of 14.46 million yuan in 2024, with a gross margin of 78.47% [4][11]. Group 2: Product Analysis - Junmaikang's sales were impacted by its late market entry and intense competition, leading to a strategic shift in sales approach [6][9]. - Mailishu's cost increased by 1,122.70% compared to the previous year, resulting in a decrease in gross margin by 9.96 percentage points [5][6]. - Maiweijian's market entry was slow, with only 75 hospitals approved by the end of 2024, attributed to its limited indications compared to the original drug [12][14]. Group 3: Market Trends and Strategies - The TNF-α drug market in China grew from 3.5 billion yuan in 2019 to 42.9 billion yuan in 2023, with a compound annual growth rate of 17.5% [6][7]. - The company plans to expand Maiweijian's indications to include SREs, which could enhance its market presence [23][24]. - The company is actively pursuing international collaborations and expanding its product pipeline to enhance revenue streams [25][26]. Group 4: Financial Outlook - The company anticipates gradual revenue growth and a reduction in net losses over the next three years, with a low risk of expanding losses [20][19]. - The company is focusing on improving operational efficiency and expanding its commercialized product offerings to achieve profitability [20][21].

Group 1: Company Developments - Yuan Da Pharmaceutical (00512.HK) announced that its partner, Taisun Pharmaceutical, successfully completed Phase II and III clinical trials for APP13007, a hormone nano-suspension eye drop, which showed significant efficacy in treating postoperative inflammation and pain [1] - Junshi Biosciences (688180.SH) reported that its PARP inhibitor, senaparib, achieved the primary endpoint in a Phase III clinical trial for advanced ovarian cancer, and plans to submit a new drug application soon [4] - Zhongyuan Jianye (09982.HK) successfully held a signing ceremony for 21 projects in Henan, with a total contracted construction area of approximately 1.9515 million square meters [5] Group 2: Sales and Financial Performance - Qiu Tai Technology (01478.HK) disclosed that it sold 37.928 million camera modules in March 2023, a month-on-month increase of 41.8%, but a year-on-year decrease of 2% [2] - China Resources Land (01109.HK) reported a total contract sales amount of approximately RMB 38.8 billion in March 2023, representing a year-on-year increase of 85.7% [3] - Far East Horizon (02163.HK) achieved a revenue of HKD 36.97 million in the first quarter, reflecting a year-on-year growth of 9.41% [7] Group 3: Market and Operational Data - China Metallurgical Group (01618.HK) signed new contracts worth RMB 325.81 billion from January to March 2023, marking a year-on-year increase of 2.1% [8] - Longyuan Power (00916.HK) completed a total power generation of 19.6033 million MWh in the first quarter, a year-on-year increase of 7.61% [8] - MONGOL MINING (00975.HK) sold 1.6 million tons of washed coking coal products in the first quarter, a year-on-year increase of 343% [8]

由上海市生物医药行业协会、上海君实生物医药科技股份有限公司、南京王京传媒广告有限公司联合主 办，上海临港（600848）奉贤经济发展有限公司、上海临港蓝湾私募基金管理有限公司共同协办的"AI 赋能生物医药行业沙龙"，于2025年5月8日在上海临港生命蓝湾圆满落幕。本次活动汇聚了生物医药行 业领袖、技术专家及知名企业代表，通过主题研讨与实地考察相结合的形式，深度探讨AI技术在药物 研发、生产制造等环节的创新应用。与会嘉宾不仅围绕行业前沿技术展开专题研讨，更实地参访了君实 生物智能工厂，切身感受AI技术对医药智能制造体系的创新性赋能。 主持人：马 骏 上海君实生物医药科技股份有限公司副总经理 上海市生物医药行业数字化转型专委会副主任委员 陈少雄 执行会长、秘书长 上海市生物医药行业协会 陈会长在开幕致辞中系统阐释了上海生物医药行业协会的三大战略使命：首先，构建产学研用协同创新 平台，通过成立数字化转型专业委员会等载体，推进产业标准体系建设；其次，培育跨界融合的产业生 态，推动生物医药企业与AI技术服务商、智能装备制造商形成战略联盟，加速智能解决方案在真实场 景中的产业化应用；第三，打造全球创新枢纽，依托临港新片区 ...

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualan Biological Engineering, and others [4]. Core Viewpoints - The report highlights the investment opportunities in innovative drugs against the backdrop of global asset rebalancing, particularly focusing on KRAS G12C mutation in non-small cell lung cancer (NSCLC) [2][8]. - It emphasizes the potential for KRAS G12C inhibitors to advance to first-line treatment for NSCLC, with an estimated 30% of KRAS mutations in NSCLC being of the G12C subtype, leading to approximately 30,000 new cases annually in China [5][17]. Summary by Sections 1. Industry Viewpoints and Investment Recommendations - KRAS G12C inhibitors are progressing towards first-line treatment for NSCLC, with current standard therapies being PD1 ± chemotherapy [18]. - The report suggests focusing on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market, with significant data releases expected from major conferences [6][32]. 2. Pharmaceutical Industry Market Performance - The pharmaceutical sector saw a 1.01% increase, slightly underperforming the CSI 300 index by 1.00 percentage points [39]. - Sub-sectors such as drug packaging and medical devices performed well, while innovative drugs lagged behind [39]. 3. Company Dynamics - Notable company activities include the approval of new drugs and clinical trial advancements, such as the successful Phase III trials for AstraZeneca's Breztri and Genmab's Epcoritamab [46]. - Companies like Junshi Biosciences and Innovent Biologics are highlighted for their leading positions in the KRAS G12C inhibitor market [22][23]. 4. Industry Dynamics - The report discusses the impact of patent expirations on raw material demand, projecting a significant increase in sales due to the expiration of patents for top-selling small molecule drugs [35]. - It also notes the improvement in demand for raw materials and the end of inventory destocking phases, suggesting a positive outlook for the raw material sector [35].